ISSN: 2161-119X

Отоларингология: открытый доступ

Открытый доступ

Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.

 

Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей

Индексировано в
  • Индекс Коперника
  • Google Scholar
  • Шерпа Ромео
  • Открыть J-ворота
  • Генамика ЖурналSeek
  • РефСик
  • Университет Хамдарда
  • ЭБСКО, Аризона
  • OCLC- WorldCat
  • Публикации
  • Женевский фонд медицинского образования и исследований
  • ICMJE
Поделиться этой страницей

Абстрактный

The Effectiveness of Epinastine Hydrochloride for Pediatric Sleep- Disordered Breathing Related Symptoms Caused By Hyperesthetic Non- Infectious Rhinitis

Hirotaka Hara *,Kazuma Sugahara ,Takefumi Mikuriya ,Makoto Hashimoto ,Shinsaku Tahara ,Hiroshi Yamashita

Objectives: The aims of this study were to prospectively evaluate the effectiveness of oral epinastine hydrochloride in pediatric outpatients with Sleep-Disordered Breathing- (SDB) related symptoms caused by hyperesthetic non-infectious rhinitis, and to assess their Quality of Life (QOL) prior to and following treatment.

Study design: Prospective

Methods: Pediatric outpatients (9 boys and 10 girls; average age, 5.6 years [SD=1.4]), with SDB related symptoms influenced by hyperesthetic non-infectious rhinitis were recruited. The children were all treated with oral epinastine hydrochloride dry syrup for 4 weeks. Before and after the 4-week treatment period, the following data were collected from each participant: otolaryngological findings, obstructive sleep apnea-18 (OSA-18) scores, and evaluation of QOL.

Results: Epinastine hydrochloride significantly improved the swelling of the inferior nasal turbinate mucosa and decreased the quantity of nasal discharge. The initial total mean OSA-18 score was 58.5, whereas the total score reduced to 22.8 after oral epinastine hydrochloride treatment. Significant (p < 0.01) differences were found between pre- and post-treatment total OSA-18 scores as well as pre- and post-treatment measurements of domains of sleep disturbance, physical symptoms, and caregiver concerns.

Conclusions: Epinastine hydrochloride therapy may improve nasal findings and QOL in pediatric outpatients with SDB related symptoms caused by hyperesthetic non-infectious rhinitis.